Indication
Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease is an inherited multisystem disorder primarily affecting the renal and cardiovascular systems, typically manifesting clinically in adulthood. Read more about Autosomal dominant polycystic kidney disease
3 drugs 3 manufacturers
Drugs that treat it
Common Autosomal dominant polycystic kidney disease therapies.
TOLVAPTAN
TOLVAPTAN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAutosomal dominant polycystic kidney disease is an inherited multisystem disorder primarily affecting the renal and cardiovascular systems, typically manifesting clinically in adulthood.
It is pathologically driven by mutations in genes such as *PKD1* or *PKD2*, which lead to aberrant tubular epithelial cell proliferation and fluid secretion.
This causes the progressive, bilateral formation and enlargement of fluid-filled renal cysts that disrupt kidney architecture, resulting in flank pain, early-onset hypertension, hematuria, and a gradual decline toward end-stage renal disease.
Significant extrarenal manifestations also frequently occur, including hepatic cysts, cerebral intracranial aneurysms, and cardiac valvular abnormalities.
- medlineplus.gov
Autosomal dominant polycystic kidney disease is an inherited multisystem disorder primarily affecting the renal and cardiovascular systems, typically manifesting clinically in adulthood This causes the progressive, bilateral formation and enlargement of fluid-filled renal cysts that disrupt kidney architecture, resulting in flank pain, early-onset hypertension, hematuria, and a gradual decline toward end-stage renal disease Significant extrarenal manifestations also frequently occur, including h...
- nih.gov
Autosomal dominant polycystic kidney disease is an inherited multisystem disorder primarily affecting the renal and cardiovascular systems, typically manifesting clinically in adulthood It is pathologically driven by mutations in genes such as *PKD1* or *PKD2*, which lead to aberrant tubular epithelial cell proliferation and fluid secretion This causes the progressive, bilateral formation and enlargement of fluid-filled renal cysts that disrupt kidney architecture, resulting in flank pain, early...
- nih.gov
It is pathologically driven by mutations in genes such as *PKD1* or *PKD2*, which lead to aberrant tubular epithelial cell proliferation and fluid secretion
Personalize your experience
Follow Autosomal dominant polycystic kidney disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.